Dopamine Uptake Sites and Dopamine Receptors in Parkinson’s Disease and Schizophrenia

1990 ◽  
Vol 30 (1) ◽  
pp. 9-14 ◽  
Author(s):  
R.K.B. Pearce ◽  
P. Seeman ◽  
K. Jellinger ◽  
W. Tourtellotte
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Receptors ◽  
Dopamine Uptake ◽  
Dopamine Uptake Sites ◽  
Uptake Sites

[3H]GBR 12935 binding to dopamine uptake sites: subcellular localizatio and reduction in Parkinson's disease and progressive supranuclear palsy

1988 ◽  
Vol 156 (3) ◽  
pp. 331-340 ◽  
Author(s):  
Jean-Marie Maloteaux ◽  
Marie-Agnes Vanisberg ◽  
Christian Laterre ◽  
France Javoy-Agid ◽  
Yves Agid ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Progressive Supranuclear Palsy ◽  
Dopamine Uptake ◽  
Dopamine Uptake Sites ◽  
Uptake Sites

Autoradiography of dopamine receptors and dopamine uptake sites in the spontaneously hypertensive rat

1990 ◽  
Vol 25 (5) ◽  
pp. 703-709 ◽  
Author(s):  
Kayoko Kujirai ◽  
Serge Przedborski ◽  
Vladimir Kostic ◽  
Vernice Jackson-Lewis ◽  
Stanley Fahn ◽  
...  
Keyword(s):  
Dopamine Receptors ◽  
Spontaneously Hypertensive Rat ◽  
Dopamine Uptake ◽  
Spontaneously Hypertensive ◽  
Hypertensive Rat ◽  
Dopamine Uptake Sites ◽  
Uptake Sites

An Exploratory Retrospective Evaluation of Ropinirole-Associated Psychotic Symptoms in an Outpatient Population Treated for Restless Legs Syndrome or Parkinson's Disease

2009 ◽  
Vol 43 (9) ◽  
pp. 1426-1432 ◽  
Author(s):  
Steven C Stoner ◽  
Megan M Dahmen ◽  
Mignon Makos ◽  
Jessica W Lea ◽  
Lora J Carver ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Receptors ◽  
Restless Legs Syndrome ◽  
Dopamine Agonists ◽  
Dual Therapy ◽  
Psychotic Symptoms ◽  
Antipsychotic Treatment ◽  
Restless Legs ◽  
Psychotic Features

Background: Traditional treatment approaches for the management of restless legs syndrome (RLS) and Parkinson's disease (PD) include the use of medications that either directly or indirectly increase dopamine levels. In turn, a potential adverse event that could be expected is the development or exacerbation of psychiatric-related symptoms. Objective: To evaluate and describe the incidence of psychosis and associated behavioral features in patients taking ropinirole for RLS or PD. Methods: Patients were identified from a computerized database search of outpatients being treated with ropinirole for 1 of 2 medical conditions: PD or RLS. Data were collected in a retrospective manner from 95 patients who were tracked over the course of their therapy to determine whether psychosis or associated behavioral symptoms developed as a result and whether an intervention was needed to adjust ropinirole dosing or if additional medications had to be added to control features associated with psychosis. Results: A total of 284 patients being treated for RLS or PD were identified; of this group, 95 patients were identified as being treated for PD or RLS with ropinirole. Of the 95 patients being treated with ropinirole, 13 developed psychotic features that required therapeutic intervention with either the use of an antipsychotic or dose adjustment of ropinirole. PD patients included in this study were numerically more likely to develop psychotic features compared with RLS patients; however, the difference was not statistically significant (p = 0.122). The results do suggest that this risk is increased when ropinirole is used as part of a dual therapy approach with dopamine agonists in the treatment of either PD or RLS (p = 0.003). Discussion: Dopamine agonists have long been used as preferred treatment in the management of PD and RLS. When treating either PD or RLS in the psychiatric population, the concern arises that increased activity at dopamine receptors may induce or exacerbate psychiatric features. A potential clinical concern with the use of ropinirole is the potential for patients to develop psychiatric features, although there are few data available to demonstrate whether stimulation of targeted individual dopamine receptors is linked to the development or exacerbation of psychotic features. It is also undetermined whether concurrent antipsychotic treatment provides any protective benefit against psychosis, especially in patients already being treated for psychotic symptoms. Conclusions: Our findings suggest that ropinirole may play a role in inducing or exacerbating psychosis and its associated features, although a number of confounding variables prevent the determination of a clear association and suggest that further investigation is warranted in controlled clinical trials.

[3H]GBR-12935 binding to dopamine uptake sites in the human brain

1988 ◽  
Vol 457 (1) ◽  
pp. 122-129 ◽  
Author(s):  
Jan Marcusson ◽  
Kristina Eriksson
Keyword(s):  
Human Brain ◽  
Dopamine Uptake ◽  
Dopamine Uptake Sites ◽  
Uptake Sites
Sign in / Sign up

Export Citation Format

Share Document